Seven Clinical Trial Read-Outs Due In Q4
Executive Summary
The last three months of the year should see data reporting from a number of key studies for novel products including Roche's emicizumab. Scrip takes a look at some of the more interesting studies expected by year end, with the help of analysts from Informa's Biomedtracker.
You may also be interested in...
Galectin Offers Subgroup Approach For Struggling NASH Candidate
Having failed to meet its primary endpoint in consecutive Phase II studies, Galectin hopes to move GR-MD-02 forward in NASH in patients with cirrhosis who have not developed esophageal varices.
Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern
Genentech/Roche's Hemlibra, now FDA-approved for hemophilia A patients with inhibitors, offers a once-weekly injection, impressive efficacy with a safety concern that appears to be manageable, and a price that's at least half the cost of the established prophylaxis regimen.
Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure
Axovant's stock fell 74% based on intepirdine's Phase III failure, but parent company Roivant recently raised $1.1bn, showing that investors were willing to fund more new Vants regardless of the risky study's outcome.